CYTEA BIO
Jessy Presumey is a seasoned researcher with extensive experience in immunology and molecular medicine. Currently serving as Head of Research at CYTEA|BIO since November 2022, Jessy previously held roles such as Head of Science and Chief Operating Officer at MedXCell NKar, and Project Manager R&D. A former Postdoctoral Researcher at Boston Children's Hospital, Jessy developed innovative mouse models utilizing CRISPR/Cas9 technology and explored the implications of Complement C4 in neural development and lupus. Jessy earned a PhD in Immunology from the University of Montpellier and has additional degrees in Immunology and Biology from Aix-Marseille University, Université de Bourgogne, and University of Montpellier.
This person is not in any teams
CYTEA BIO
CYTEA BIO is a pre-clinical stage biotech company developing therapeutic products by combining genetically unmodified effector cells and engineered targeting ligands. Its patented Pin™ Platform enables practically limitless combinations of effector mechanisms and targeting ligands for applications in oncology and immunology. CYTEA BIO is the first portfolio company of MedXCell, a European cell therapy venture builder with offices in Switzerland, France and the US. MedXCell focuses on technologies, techniques or novel applications in major diseases such as cancer, autoimmune, neurological and degenerative disorders, with the aim to turn promising academic ideas into commercially viable propositions.